Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Sujata M. Bhavnani"'
Autor:
M. Courtney Safir, Sujata M. Bhavnani, Christine M. Slover, Paul G. Ambrose, Christopher M. Rubino
Publikováno v:
Antibiotics, Vol 9, Iss 7, p 412 (2020)
It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, compan
Externí odkaz:
https://doaj.org/article/bbd1d0f52f5c412a87b761932369bf2f
Autor:
John P O’Donnell, Sujata M Bhavnani
Publikováno v:
Clinical Infectious Diseases. 76:S202-S209
Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of
Autor:
Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired
Autor:
Sujata M Bhavnani, Jeffrey P Hammel, Harish Ganesan, M Courtney Safir, Christopher M Rubino, Paul G Ambrose, Kevin M Krause
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentrates in alveolar macrophages and exhibits potent activity against nontuberculous mycobacteria. PK-PD target attainment (PTA) analyse
Publikováno v:
Open Forum Infectious Diseases. 9
Background Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which have higher predisposition to develop antifungal resistance (e.g., fks mutations conferring reduced susceptibility to echinocandins)
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria, is under clinical development for treatment of MAC lung disease. A population pharmacokine
Autor:
Sujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, Anthony P Cammarata, Kajal Larson, Kathryn Liolios, Sarah McLeod, Alita Miller, Paul G Ambrose, Ruben Tommasi, John O'Donnell
Publikováno v:
Open Forum Infectious Diseases. 9
Background SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, which are often severe and associated with substantial mortality. PPK, PTA, and clinical PK/PD analyses were conducted using all
Autor:
Jill Lindley, Timothy B Doyle, Brian D VanScoy, Christopher M Rubino, Sujata M Bhavnani, Paul G Ambrose, Mariana Castanheira
Publikováno v:
Open Forum Infectious Diseases. 8:S629-S631
Background Escherichia coli ST131 is a major challenge for global human health. Among ST131 isolates, the H30 type is prevalent and displays multiple drug resistance to classes. A monoclonal antibody (mAb) specific for the O antigen, O25b, which is c
Autor:
Dayton W. Yuen, Nikolas J. Onufrak, Christopher M. Rubino, Jakko van Ingen, David E. Griffith, Kevin C. Mange, Kevin L. Winthrop, Sujata M. Bhavnani
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
European Journal of Drug Metabolism and Pharmacokinetics, 46, 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 2, pp. 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 2, pp. 277-287
Background and Objectives Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to
Autor:
Haley Conde, Brian VanScoy, Sujata M. Bhavnani, Nicole E. Scangarella-Oman, Steven Fikes, Elizabeth A Lakota, Philippa Elefante, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action with an in vitro spectrum of activity that includes Escherichia coli. Our objectives herein were the foll